π-Clamp-Mediated Homo- and Heterodimerization of Single-Domain Antibodies via Site-Specific Homobifunctional Conjugation

Ross J. Taylor, Mauricio Aguilar Rangel, Michael B. Geeson, Pietro Sormanni, Michele Vendruscolo,* and Gonçalo J. L. Bernardes*

ABSTRACT: Post-translational protein–protein conjugation produces bioconjugates that are unavailable via genetic fusion approaches. A method for preparing protein–protein conjugates using π-clamp-mediated cysteine arylation with pentafluorophenyl sulfonamide functional groups is described. Two computationally designed antibodies targeting the SARS-CoV-2 receptor binding domain were produced (K_D = 146, 581 nM) with a π-clamp sequence near the C-terminus and dimerized using this method to provide a 10–60-fold increase in binding (K_D = 8–15 nM). When two solvent-exposed cysteine residues were present on the second protein domain, the π-clamp cysteine residue was selectively modified over an Asp-Cys-Glu cysteine residue, allowing for subsequent small-molecule conjugation. With this strategy, we build molecule–protein–protein conjugates with complete chemical control over the sites of modification.

The generation of protein–protein conjugates plays an important role in advancing the fields of biotechnology and biopharmaceutical research. Their applications include uses as therapeutic bispecific antibodies, bioimaging reagents, and bifunctional enzymes.1–3 These conjugates are typically accessed by recombinantly expressing proteins fused at the genetic level.4,5 Limitations of fusion proteins include incorrect folding of the constituent domains, poor stability, incompatibility of some conjugation partners, and the necessity for N-to-C terminal fusion.6,7 These limitations have spurred a search for alternative approaches.8

Post-translational protein–protein conjugation strategies are alternatives that permit greater diversity in the resulting conjugates, such as N-to-N, C-to-C, or even internally linked conjugates.9,10 Strategies to achieve this include chemically installed click handles,11–12 enzymatic conjugation, tag-based and noncanonical amino acid-based methods,13–19 heterobifunctional linking,20–23 and homobifunctional linking.24–30 The latter of these has an inherently simple workflow (Figure 1); the linkers are easily synthesized, and diverse linker motifs can be incorporated into protein–protein conjugates.

Cysteine-reactive bismaleimide molecules linked by polyethylene glycol (PEG) units are the prototypical reagents for homobifunctional linking (Figure 1).24,27,31,32 Although they exhibit fast kinetics, the resulting linkages can undergo retro-Michael addition and subsequent thiol exchange with endogenous thiols found in serum.33,34 While attempts to overcome these challenges have been made,28–30,35 these examples have other drawbacks such as required hydrolysis at 37 °C, limited potential for linker diversification, or exclusive targeting of disulfide bonds. We describe a homobifunctional linking strategy that bypasses these caveats, based on cysteine arylation with perfluoroaromatic reagents, resulting in stable S–C(sp²) bonds via S_NAr.36–39 Pentafluorophenyl (PFP) sulfonamide derivatives are reactive toward solvent-exposed cysteine residues under mild aqueous conditions, attributable to activation of the fluoride substituent para to the electron-withdrawing sulfonamide group.40 The π-clamp sequence (Phe-Cys-Pro-Phe), previously described by Pentelute et al.,40,41 significantly enhances the reactivity of the included cysteine with perfluoroaromatic compounds and has been used to generate antibody–drug conjugates (ADCs) and in PROTAC development.40,42,43 Here we show that the π-clamp motif is essential for producing protein–protein dimers via cysteine arylation with PFP-sulfonamide linkers and describe the first molecule–protein–protein conjugates site-specifically generated using π-clamp chemistry (Figure 1).

This linking strategy generated homo- and heterodimers of computationally designed antibodies (desAbs) targeting two distinct epitopes on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, named C1 and C2 (Figure 2). These antibodies possess modest K_D values (146 and 581 nM, respectively), making them an ideal system for testing affinity maturation via dimerization.44 The small size of single-domain antibodies (sdAbs) used as the desAb scaffold makes them susceptible to rapid clearance in vivo, so an increase in size and binding affinity could improve the half-life.45 Additionally, in the context of sdAbs, the paratope is sometimes proximal to the N-terminus, which means that traditional N-to-C ligation can impede binding to the target epitopes.25
under mild conditions (Figure 3b and Table S4). A control conversion to the modified monomer (significantly more reactive than with an excess of L1) for conversion to a fully modified monomer after incubation C1-DCE the reactivity of more reactive PFP-sulfonamides. Therefore, given the poor ment observed with perfluoroaromatics would also hold with (Tables S1 and S2).

Figure 1. Left: Workflows for producing homodimers, heterodimers, and site-specifically labeled heterodimers. Right: Comparison of maleimide-based and pentafluorophenyl sulfonamide-based homobifunctional reagents. FG: functional group. C: cysteine residue.

Conjugation, however, enables conjugation of monomers through their C-terminal regions.

We initially focused on using a homobifunctional reagent featuring cysteine-reactive PFP-sulfonamide groups on either end of a flexible and water-soluble PEG-2 linker, L1 (Figure 3). A solvent-exposed cysteine residue was engineered into the antibody in an Asp-Cys-Glu motif immediately before a C-terminal tobacco etch virus (TEV) cleavage site and His tag (C1-DCE). It quickly became evident that the cysteine residue (0.5 equiv) for 24 h under forcing conditions (Tris-HCl, 20 mM, pH 8.5, 37 °C, 24 h) (Figure 3a and Table S3). In addition, the reactivity of the cysteine residue in C1-DCE was not sufficient for conversion to a fully modified monomer after incubation with an excess of L1 for 24 h under several sets of conditions (Tables S1 and S2).

We rationalized that the π-clamp mediated rate enhancement observed with perfluoroaromatics would also hold with more reactive PFP-sulfonamides. Therefore, given the poor reactivity of C1-DCE, we engineered a π-clamp sequence into the C1 antibody to produce C1-π (Figure 1). C1-π was significantly more reactive than C1-DCE and underwent full conversion to the modified monomer (C1-L1) within 3–5 h under mild conditions (Figure 3b and Table S4). A control alanine variant of C1-π (C1-ACPA, Ala-Cys-Pro-Ala) was prepared to confirm the π-clamp as the source of increased reactivity. Accordingly, C1-ACPA did not undergo dimerization under conditions otherwise identical to those used for C1-π (Figure S22), even in the presence of excess L1 at both pH 8.0 and 8.5 (Table S4). These results demonstrate the π-clamp is essential for dimerization and is also important for efficiency of the initial conjugation reaction.

Upon incubation of C1-π in the presence of L1 (0.5 equiv) for 24 h, homodimer C1C1-L1 was efficiently produced (Figure 3b). Purification by size-exclusion chromatography (SEC) allowed C1C1-L1 to be isolated in 55% yield. The purity of C1C1-L1 was confirmed by LC−MS (Figure 3d) and SDS-PAGE analyses (Figure 3g). The related family of antibodies C1, C1-π, and C1C1-L1 were characterized by a suite of biophysical techniques, including circular dichroism and Tycho thermal denaturation (Figure 3e,f), which assessed the impact of conjugation upon the secondary structure and thermal stability, respectively. Negligible structural perturbation was observed among C1C1-L1, C1-π, and C1, highlighting the mild nature of the conjugation conditions.

The homobifunctional linking strategy was initially devised to overcome the reversibility of traditional maleimide linkers. To assess this, both C1C1-L1 and an analogous dimer produced using a bismaleimide reagent, C1C1-M (Figure S33), were incubated with excess glutathione at 37°C for 3 days. Time points taken over this period showed decomposition of C1C1-M to its constituent monomers, while C1C1-L1 remained intact, confirming the stability of PFP-sulfonamide-linked antibodies compared with the maleimide equivalents (Figure S36).

Linker length is an important parameter for modulating the binding properties of bioconjugates, and it is usually tuned by increasing the number of amino acids in genetic fusion or PEG units in post-translational modification, respectively. Therefore, we synthesized L2, a PFP-sulfonamide linker featuring a PEG-5 linker. L2 was used to generate C1C1-L2 in a manner identical to that for C1C1-L1, and C1C1-L2 was isolated in 51% yield (Figure 3b). An equivalent π-clamp sequence was inserted near the C-terminus of C2 to prepare C2-π, which was subsequently used to produce C2C2-L2 in an isolated yield of 32% (Figure 3b). These conjugates were found to have high purity and stability as well as biophysical characteristics consistent with those of their parent monomers (Figure 3d–g).
Because of the trimeric nature of the spike protein, homodimeric bivalent antibodies could theoretically bind once to each spike protein through two RBDs (Figure 2). However, it has been shown that the spike protein is in dynamic equilibrium with “up” and “down” RBD conformations.

It was unclear whether the epitopes would be fully accessible in the “down” conformation, rendering the bivalent homodimers unable to bind twice to the same spike. With this in mind, the biparatopic heterodimer (C1C2-L2), which is capable of binding to both exposed epitopes of a single RBD in the “up” conformation, was produced. Sequential conjugation steps were carried out to access the heterodimer C1C2-L2 (Figure 3c). First, C1-π was incubated with an excess of L2 for 3 h prior to purification via SEC and isolated in 48% yield. In a second step, purified C1-L2 was incubated with C2-π (∼1.2 equiv) for 24 h to produce and isolate C1C2-L2 in 38% yield (over two steps: 17%) with high purity and stability (Figure 3d–g).

Intrigued by the necessity for the π-clamp cysteine residue in the second conjugation reaction, we investigated the specificity for the π-clamp cysteine when more than one solvent-exposed cysteine environment was present in the second domain. To do this, we devised an experiment in which the second C1 antibody to be sequentially conjugated had a π-clamp sequence upstream of a TEV cleavage site and an Asp-Cys-Glu motif downstream (C1-π-DCE). This antibody allowed the production of the heterodimer C1-π/C1-π-DCE-L2 with a single solvent-exposed cysteine residue, which was isolated in 33% yield (over two steps: 21%) (Figure 4a,b). The solvent-exposed, reactive cysteine residue was subsequently treated with Alexa-647 maleimide to functionalize the dimer with a fluorophore (Figure 4b,c). Following this, the TEV recognition sequence was cleaved by TEV protease, concomitantly releasing the Asp-Cys-Glu sequence and thus the Alexa-647 dye. The resulting mixture was purified by immobilized metal affinity chromatography to remove the His-tagged peptides. Upon analysis of the pre- and post-TEV-cleavage mixtures by LC–MS (Figures S34 and S35) and SDS-PAGE, visualized using an Alexa-647 filter or Coomassie stain (Figure 4c), only dimeric antibody species were observed. This clearly indicated that dimerization must have proceeded solely through the π-clamp. If dimerization had occurred through the Asp-Cys-Glu motif, TEV cleavage would have resulted in deconjugation of the antibody domains and observation of monomer labeled

Figure 3. Preparation of desAb dimers using PFP-sulfonamide linkers: (a) C1-DCE; (b) homodimers; (c) heterodimers. Characterization of products by (d) LC–MS, (e) circular dichroism, (f) Tycho thermal denaturation, and (g) SDS-PAGE.
with Alexa-647 through the π-clamp cysteine residue. Monomeric antibody species were not present after TEV cleavage, demonstrating the specificity of the second conjugation step for the π-clamp cysteine residue.

After confirming the purity, stability, and site specificity of the conjugation strategy, we assessed the effect of dimerization on the apparent antibody $K_D$. Initially, the $K_D$ values for all of the homodimer constructs were measured by microscale thermophoresis (MST), a technique that relies on equilibrium thermodynamics in solution. The homodimers displayed a 10−60-fold improvement in apparent $K_D$ with respect to their constituent monomers (Figure 5a). This is in line with expectation for a biparatopic conjugate accessing proximal epitopes on the spike, as it results in slower dissociation of the binder due to the “forced proximity effect”, i.e., increased avidity. All of the homodimers had comparable avidities, a surprising effect given the initial difference in monomer affinities. In addition, the linker length had a negligible effect on the avidity of C1C1 constructs. Interestingly, the heterodimeric and biparatopic C1C2-L2 did not show any further improvement compared to the bivalent homodimer constructs (Figure 5a), suggesting a similar mode of binding for all of the antibody dimers produced. As a negative control, the binding of a computationally designed anti-human serum albumin antibody (P2) to the spike protein was assessed by MST, and no binding was observed (Figure 5a). In addition, the PFP-sulfonamide linkers had no effect on $K_D$ compared to the bismaleimide linker of C1C1-M (Figure 5a).

Because of the aforementioned equilibrium of “up” and “down” conformations of the RBD, the mode of binding of the homodimeric, bivalent antibodies to the spike protein was investigated. We envisioned two possible scenarios: (i) both units of the dimer bind to two RBDs on the same spike; (ii) each unit of the dimer binds to an RBD on a different spike molecule. The second scenario would result in a dramatically increased hydrodynamic radius ($R_h$) of the complex (Figure 5b). To assess this, the spike protein was incubated with varying concentrations of C1C1-L2, and $R_h$ was measured by microfluidic diffusional sizing. Minimal variation in $R_h$ for the bound and unbound states was observed (Figure 5b), indicating that the entropically favored bidentate mode of binding to the spike protein is operational. As a control experiment, the C1-π monomer produced an invariant $R_h$ value (Figure 5b).

PFP-sulfonamide-based linking reagents enabled the generation of bivalent and biparatropic antibody homo- and heterodimers of C1 and C2. This mild conjugation approach maintained the structural integrity of the constituent domains while generating conjugates with enhanced stability compared with bismaleimide conjugation. The antibody dimers produced an order of magnitude improvement in binding to the spike protein relative to the parent monomers, due to avidity effects. In addition, the specificity of the PFP-sulfonamide function-
ality for \( \pi \)-clamp cysteine residues allowed labeling of other solvent-exposed cysteine residues. This novel feature of the PFP-sulfonamide linkers will enable the generation of bivalent, biperatopic, or bispecific ADCs, which have the potential to be powerful therapeutics.

**ASSOCIATED CONTENT**

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/10.1021/jacs.2c04747.

Detailed methods, characterization data, and additional figures (PDF)

**AUTHOR INFORMATION**

Corresponding Authors

Michele Vendruscolo — Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.; orcid.org/0000-0002-3616-1610; Email: mv245@cam.ac.uk

Gonçalo J. L. Bernardes — Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; orcid.org/0000-0001-6594-8917; Email: gb453@cam.ac.uk

Authors

Ross J. Taylor — Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.

Mauricio Aguilar Rangel — Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.

Michael B. Geeson — Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.; orcid.org/0000-0002-9228-7947

Pietro Sormanni — Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.

Complete contact information is available at: https://pubs.acs.org/10.1021/jacs.2c04747

Notes

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

This project received funding from the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/M01194 to R.J.T.) and the European Molecular Biology Organisation (EMBO) (ALTF 1148-2020 to M.B.G.). M.A.R. acknowledges support from the Protein Interactions and Stability in Medicine and Genomics Challenge Programme (PRISM; NNF18OC0033950) funded by the Novo Nordisk Foundation. P.S. is a Royal Society University Research Fellow (URF \( \backslash R1 \) 201461).

**REFERENCES**

(1) Yu, K.; Liu, C.; Kim, B.-G.; Lee, D.-Y. Synthetic fusion protein design and applications. *Biotechnol. Adv.* 2015, 33, 155–164.

(2) Ma, J.; Mo, Y.; Tang, M.; Shen, J.; Qi, Y.; Zhao, W.; Huang, Y.; Xu, Y.; Qian, C. Bispecific Antibodies: From Research to Clinical Application. *Front. Immunol.* 2021, 12, 626616.

(3) Yuste, R. Fluorescence microscopy today. *Nat. Methods* 2005, 2, 902–904.

(4) Iturrate, L.; Sánchez-Moreno, I.; Oroz-Guinea, I.; Pérez-Gil, J.; García-Junceda, E. Preparation and Characterization of a Bisfunctional Aldolase/Kinase Enzyme: A More Efficient Biocatalyst for C-C Bond Formation. *Chem. - Eur. J.* 2010, 16, 4018–4030.

(5) Zhang, J.; Yun, J.; Shang, Z.; Zhang, X.; Pan, B. Design and optimization of a linker for fusion protein construction. *Prog. Nat. Sci.* 2009, 19, 1197–1200.

(6) Bell, M. R.; Engleka, M. J.; Malik, A.; Strickler, J. E. To fuse or not to fuse: What is your purpose? *Protein Sci.* 2013, 22, 1466–1477.

(7) Szijj, P.; Chudasama, V. The renaissance of chemically generated bispecific antibodies. *Nat. Rev. Chem.* 2021, 5, 78–92.

(8) Baillmann, M.; Neises, L.; Bitsch, S.; Schneider, H.; Deweid, L.; Werther, P.; Ilkenhans, N.; Wolfring, M.; Ziegler, M. J.; Wilhelm, J.; Kolmar, H.; Wombacher, R. A Bioorthogonal Click Chemistry Toolbox for Targeted Synthesis of Branched and Well-Defined Protein–Protein Conjugates. *Angew. Chem., Int. Ed.* 2020, 59, 12885–12893.

(9) Natarajan, A.; Du, W.; Xiong, C.-Y.; DeNardo, G. L.; DeNardo, S. J.; Gervay-Hague, J. Construction of di-scFv through a trivalent alkyne–azide 1,3-dipolar cycloaddition. *Chem. Commun.* 2007, 695–697.

(10) Schellinger, J. G.; Kudupudi, A.; Natarajan, A.; Du, W.; DeNardo, S. J.; Gervay-Hague, J. A general chemical synthesis platform for crosslinking multivalent single chain variable fragments. *Org. Biomol. Chem.* 2012, 10, 1521–1526.

(11) Maruani, A.; Szijj, P. A.; Bahou, C.; Nogueira, J. C. F.; Caddick, S.; Baker, J. R.; Chudasama, V. A Plug-and-Play Approach for the De Novo Generation of Dually Functionalized Bispecifics. *Bioconjugate Chem.* 2020, 31, 520–529.

(12) Istrate, A.; Geeson, M. B.; Navo, C. D.; Sousa, B. B.; Marques, M. C.; Taylor, R. J.; Journeaux, T.; Oehler, S. R.; Mortensen, M. R.; Deery, M. J.; Bond, A. D.; Corzana, F.; Jiménez-Osés, G.; Bernardes, G. J. L. Platform for Orthogonal N-Cysteine-Specific Protein Modification Enabled by Cyclopropenone Reagents. *J. Am. Chem. Soc.* 2022, 144, 10396–10406.

(13) Krueger, A. T.; Kroll, C.; Sanchez, E.; Griffith, L. G.; Imperiali, B. Tailoring Chimeric Ligands for Studying and Biasing ErbB Receptor Family Interactions. *Angew. Chem., Int. Ed.* 2014, 53, 2662–2666.

(14) Witte, M. D.; Cragnolini, J. J.; Dougan, S. K.; Yoder, N. C.; Popp, M. W.; Ploegh, H. L. Preparation of unnatural N-to-N and C- to-C protein fusions. *Proc. Natl. Acad. Sci. U.S.A.* 2012, 109, 11993–11998.

(15) Lobba, M. J.; Fellmann, C.; Marmelstein, A. M.; Maza, J. C.; Kissman, E. N.; Robinson, S. A.; Staahl, B. T.; Urnes, C.; Lew, R. J.; Mogilevsky, C. S.; Doudna, J. A.; Francis, M. B. Site-Specific Bioconjugation through Enzyme-Catalyzed Tyrosine–Cysteine Bond Formation. *ACS Cent. Sci.* 2020, 6, 1564–1571.

(16) Stengel, A.; Gerlach, M.; Kasper, M.-A.; Hackenberger, C. P. R.; Leonhardt, H.; Schumacher, D.; Helma, J. TuPPL: Tub-tag mediated C-terminal protein–protein-ligation using complementary click-chemeristry handles. *Org. Biomol. Chem.* 2019, 17, 4964–4969.

(17) Hofmann, R.; Akimoto, G.; Schütte, T. G.; Zeysmer, C.; Bode, J. W. Lysine acylation using conjugating enzymes for site-specific modification and ubiquitination of recombinant proteins. *Nat. Chem.* 2020, 12, 1008–1015.

(18) Hutchins, B. M.; Kazane, S. A.; Staflin, K.; Forsyth, J. S.; Felding-Haber, B.; Smider, V. V.; Schultz, P. G. Selective Modification Enabled by Cyclopropenone Reagents. *Org. Biomol. Chem.* 2012, 10, 9921–9926.
(20) Baumann, A. L.; Schwagerus, S.; Brot, K.; Kemnitz-Hassanin, K.; Steiger, C. E.; Triellof, N.; Schmieder, P.; Hackenberger, C. P. R. Chemically Induced Vinylphosphonothioate Electrophiles for Thiol–Thiol Bioconjugations. *J. Am. Chem. Soc.* **2020**, *142*, 9544–9552.

(21) Dhanjee, H. H.; Saebi, A.; Buslov, I.; Loffis, A. R.; Buchwald, S. L.; Pentelute, B. L. Protein–Protein Cross-Coupling via Palladium–Protein Oxidative Addition Complexes from Cysteine Residues. *J. Am. Chem. Soc.* **2020**, *142*, 9124–9129.

(22) Dhanjee, H. H.; Buslov, I.; Windsor, L. W.; Raines, R. T.; Pentelute, B. L.; Buchwald, S. L. Palladium–Protein Oxidative Addition Complexes by Aminic-Selective Acylation. *J. Am. Chem. Soc.* **2020**, *142*, 21237–21242.

(23) Wang, T.; Pisterer, A.; Kuan, S. L.; Wu, Y.; Dunnelle, O.; Lamla, M.; Müllen, K.; Weil, T. Cross-conjugation of DNA, proteins and peptides via a pH switch. *Chem. Sci.* **2013**, *4*, 1889–1894.

(24) Glennie, M. J.; McBride, H. M.; Worth, A. T.; Stevenson, G. T. Preparation and performance of bispecific F(ab′)2 antibody containing thioether-linked Fab′ gamma fragments. *J. Immunol.* **1987**, *139*, 2367–2375.

(25) Zang, B.; Ren, J.; Li, D.; Huang, C.; Ma, H.; Peng, Q.; Ji, F.; Han, L.; Jia, L. Freezing-assisted synthesis of covalent C–C linked bivalent and bispecific nanobodies. *Org. Biomol. Chem.* **2019**, *17*, 257–263.

(26) White, C. J.; Bode, J. W. PEGylation and Dimerization of Expressed Proteins under Near Equimolar Conditions with Potassium 2-Pyridyl Acyltrifluoroborates. *Expressed Proteins under Near Equimolar Conditions with Potassium 2-Pyridyl Acyltrifluoroborates.* *CE J. Cell. Mol. Bioeng.* **2021**, *15*, 1870–1882.

(27) Hvasanov, D.; Nam, E. V.; Peterson, J. R.; Pornsaksit, D.; Wiedenmann, J.; Marquis, C. P.; Thorardson, P. One-Pot Synthesis of High Molecular Weight Synthetic Heteroprotein Dimers Driven by Charge Complementarity Electrostatic Interactions. *J. Org. Chem.* **2014**, *79*, 9594–9602.

(28) Laserna, V.; Istrate, A.; Kafuta, K.; Hakala, T. A.; Knowles, T. P. J.; Alcarazo, M.; Bernardes, G. J. L. Protein Conjugation by Electrophilic Alkylation Using 5-(Alkynyl)dibenzothiophenium Triflates. *Bioconjugate Chem.* **2021**, *32*, 1570–1578.

(29) Khalili, H.; Godwin, A.; Choi, J.-w.; Lever, R.; Khaw, P. T.; Broccini, S. Fab-PEG-Fab as a Potential Antibody Mimetic. *Bioconjugate Chem.* **2013**, *24*, 1870–1882.

(30) Hull, E. A.; Livanos, M.; Miranda, E.; Smith, M. E. B.; Chester, K. A.; Baker, J. R. Homogeneous Bispecifics by Disulfide Bridging. *Bioconjugate Chem.* **2014**, *25*, 1395–1401.

(31) Scheer, J. M.; Sandoval, W.; Elliott, J. M.; Shao, L.; Luis, E.; Lewin-Koh, S.-C.; Schaefer, G.; Vanden, R. Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators. *PLoS One* **2012**, *7*, No. e51817.

(32) Kane, B. J.; Fettis, M. M.; Farhadi, S. A.; Liu, R.; Huddala, G. A. Site-Specific Cross-Linking of Galectin-1 Homodimers by Poly-ethylene glycol) Bismaleimide. *Cell. Mol. Bioeng.* **2021**, *14*, 523–534.

(33) Szijj, P. A.; Bahou, C.; Chudasama, V. Minireview: Addressing the retro-Michael instability of maleimide bioconjugates. *Drug Discovery Today: Technol.* **2018**, *30*, 27–34.

(34) Rivasco, J. M. J. M.; Faustino, H.; Trindade, A.; Gois, P. M. P. Bioconjugation with Maleimides: A Useful Tool for Chemical Biology. *Chem. - Eur. J.* **2019**, *25*, 43–59.

(35) Forte, N.; Livanos, M.; Miranda, E.; Morais, M.; Yang, X.; Rajkumar, V. S.; Chester, K. A.; Chudasama, V.; Baker, J. R. Tuning the Hydrolytic Stability of Next Generation Maleimide Cross-Linkers Enables Access to Albumin-Antibody Fragment Conjugates and tri-cFvs. *Bioconjugate Chem.* **2018**, *29*, 486–492.

(36) Embaby, A. M.; Schoeffelen, S.; Kofoed, C.; Meldal, M.; Diness, F. Rational Tuning of Fluorobenzene Probes for Cysteine-Selective Protein Modification. *Angew. Chem., Int. Ed.* **2018**, *57*, 8022–8026.

(37) Spokony, A. M.; Zou, Y.; Ling, J. J.; Yu, H.; Lin, Y.-S.; Pentelute, B. L. A Perfluoroaryl-Cysteine S\(\text{Ar}\) Chemistry Approach to Unprotected Peptide Stapling. *J. Am. Chem. Soc.* **2013**, *135*, 5946–5949.

(38) Zhang, C.; Vinogradova, E. V.; Spokony, A. M.; Buchwald, S. L.; Pentelute, B. L. Arylation Chemistry for Bioconjugation. *Angew. Chem., Int. Ed.* **2019**, *58*, 4810–4839.

(39) Brittain, W. D. G.; Coxon, C. R. Perfluoroaryl and Perfluoroheteroaryl Reagents as Emerging New Tools for Peptide Synthesis, Modification and Bioconjugation. *Chem. - Eur. J.* **2022**, *28*, No. e202103305.

(40) Zhang, C.; Welborn, M.; Zhu, T.; Yang, N. J.; Santos, M. S.; Van Voorhis, T.; Pentelute, B. L. \(\pi\)-Clamp-mediated cysteine conjugation. *Nat. Chem.* **2016**, *8*, 120–128.

(41) Dai, P.; Williams, J. K.; Zhang, C.; Welborn, M.; Shepherd, J. J.; Zhu, T.; Van Voorhis, T.; Hong, M.; Pentelute, B. L. A structural and mechanistic study of \(\pi\)-clamp-mediated cysteine perfluoroarylation. *Sci. Rep.* **2017**, *7*, 7954.

(42) Lee, M. D.; Tong, W. Y.; Nebl, T.; Pearce, L. A.; Pham, T. M.; Gollan-Hagh, A.; Puttick, S.; Rose, S.; Adams, T. E.; Williams, C. C. Dual Site-Specific Labeling of an Antibody Fragment through Sortase A and \(\pi\)-Clamp Conjugation. *Bioconjugate Chem.* **2019**, *30*, 2539–2543.

(43) Gama-Brambila, R. A.; Chen, J.; Dabiri, Y.; Tascher, G.; Néme, V.; Münch, C.; Song, G.; Knapp, S.; Cheng, X. A. Chemical Toolbox for Labeling and Degrading Engineered Cas Proteins. *JACS Au* **2021**, *1*, 777–785.

(44) Rangel, M. A.; Bedwell, A.; Costanzi, E.; Taylor, R.; Russo, R.; Bernardes, G. J. L.; Ricagno, S.; Frydman, J.; Vendruscolo, M.; Sormanni, P. Fragment-based computational design of antibodies targeting structured epitopes. *bioRxiv* **2022**, DOI: 10.1101/2021.03.02.433360.

(45) Cuesta, A. M.; Sainz-Pastor, N.; Bonet, J.; Oliva, B.; Álvarez Vallina, L. Multivalent antibodies: when design surpasses evolution. *Trends Biotechnol* **2010**, *28*, 355–362.

(46) Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **2020**, *367*, 1260–1263.

(47) Vauquelin, G.; Charlton, S. J. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. *Br. J. Pharmacol.* **2013**, *168*, 1771–1785.

(48) Yates, E. V.; Müller, T.; Rajah, L.; De Genst, E. J.; Arosio, P.; Linse, S.; Vendruscolo, M.; Dobson, C. M.; Knowles, T. P. J. Latent analysis of unmodified biomolecules and their complexes in solution with attomole detection sensitivity. *Nat. Chem.* **2015**, *7*, 802–809.